Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells

Pharmacogenomics

Volumn 12, Issue 4, 2011, Pages 503-514

  Parmar, Sumit ^a   Seeringer, Angela ^a   Denich, Dina ^a   Gärtner, Franziska ^a   Pitterle, Kai ^a   Syrovets, Tatiana ^a   Ohmle, Barbara ^a   Stingl, Julia C ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

cytarabine; cytidine deaminase; hematotoxicity; pharmacogenomics

Indexed keywords

CYTARABINE;

ADULT; ARTICLE; BLOOD TOXICITY; CELL VIABILITY; CONTROLLED STUDY; CYTIDINE DEAMINASE GENE; CYTOTOXICITY; DRUG TRANSFORMATION; DRUG TRANSPORT; EX VIVO STUDY; EXON; FEMALE; GENE; GENE DELETION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENETICS; PROMOTER REGION; RISK FACTOR; VOLUNTEER;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CELL SURVIVAL; CELLS, CULTURED; CYTARABINE; CYTIDINE DEAMINASE; DRUG TOXICITY; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EXONS; FEMALE; GENOTYPE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS; THIOINOSINE; YOUNG ADULT;

ARA;

EID: 79955540073     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.200     Document Type: Article

References (36)

1. Welsh M, Mangravite L, Medina MW et al.: Pharmacogenomic discovery using cell-based models. Pharmacol. Rev. 61(4), 413-429 (2009).
2. Zhang W, Dolan ME: Use of cell lines in the investigation of pharmacogenetic loci. Curr. Pharm. Des. 15(32), 3782-3795 (2009).
3. Tallman MS, Gilliland DG, Rowe JM: Drug therapy for acute myeloid leukemia. Blood 106(4), 1154-1163 (2005). (Pubitemid 41130866)
4. Mackey JR, Baldwin SA, Young JD, Cass CE: Nucleoside transport and its significance for anticancer drug resistance. Drug Resist. Updat. 1(5), 310-324 (1998).
5. Boleti H, Coe IR, Baldwin SA, Young JD, Cass CE: Molecular identification of the equilibrative NBMPR-sensitive (ES) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (EI) transport activity in human erythroleukemia (K562) cells. Neuropharmacology 36(9), 1167-1179 (1997). (Pubitemid 27465605)
6. Endo Y, Obata T, Murata D et al.: Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides. Cancer Sci. 98(10), 1633-1637 (2007). (Pubitemid 47308462)
7. Clarke Ml, Damaraju Vl, Zhang J et al.: The role of human nucleoside transporters in cellular uptake of 4́-thio-b-d-arabinofuranosylcytosine and b-d-arabinosylcytosine. Mol. Pharmacol. 70(1), 303-310 (2006).
8. Coleman CN, Stoller RG, Drake JC, Chabner BA: Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Blood 46(5), 791-803 (1975).
9. Plunkett W, Liliemark JO, Estey E, Keating MJ: Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin. Oncol. 14(2 Suppl. 1), 159-166 (1987).
10. Laliberte J, Momparler Rl: Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res. 54(20), 5401-5407 (1994). (Pubitemid 24336032)
11. Fitzgerald SM, Goyal RK, Osborne WR, Roy JD, Wilson JW, Ferrell RE: Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum. Genet. 119(3), 276-283 (2006).
12. Kirch HC, Schroder J, Hoppe H, Esche H, Seeber S, Schutte J: Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp. Hematol. 26(5), 421-425 (1998). (Pubitemid 28198740)
13. Gilbert JA, Salavaggione OE, Ji Y et al.: Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res. 12(6), 1794-1803 (2006).
14. Osato DH, Huang CC, Kawamoto M et al.: Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics 13(5), 297-301 (2003). (Pubitemid 36583998)
15. Myers SN, Goyal RK, Roy JD, Fairfull LD, Wilson JW, Ferrell RE: Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet. Genomics 16(5), 315-320 (2006).
16. Lamba JK, Crews K, Pounds S et al.: Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J. Pharmacol. Exp. Ther. 323(3), 935-945 (2007). (Pubitemid 350146062)
17. Joerger M, Bosch TM, Doodeman VD, Beijnen JH, Smits PH, Schellens JH: Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. Eur. J. Clin. Pharmacol. 62(8), 681-684 (2006). (Pubitemid 44127999)
18. Kessel D, Hall TC, Rosenthal D: Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro. Cancer Res. 29(2), 459-463 (1969).
19. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263-265 (2005). (Pubitemid 40202029)
20. Lewontin RC: The interaction of selection and linkage. II. Optimum models. Genetics 50, 757-782 (1964).
21. Stephens M, Donnelly P: A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73(5), 1162-1169 (2003). (Pubitemid 37414228)
22. Bhatla D, Gerbing RB, Alonzo TA et al.: Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br. J. Haematol. 144(3), 388-394 (2009).
23. Mahlknecht U, Dransfeld CL, Bulut N et al.: SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia 23(10), 1929-1932 (2009).
24. Sarkar M, Han T, Damaraju V, Carpenter P, Cass CE, Agarwal RP: Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. Biochem. Pharmacol. 70(3), 426-432 (2005). (Pubitemid 40905114)
25. Mata JF, Scrideli CA, Queiroz RP et al.: Cytosine arabinoside- metabolizing enzyme genes are underexpressed in children with MLL gene-rearranged acute lymphoblastic leukemia. Braz. J. Med. Biol. Res. 39(11), 1417-1423 (2006). (Pubitemid 46357857)
26. Hubeek I, Stam RW, Peters GJ et al.: The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br. J. Cancer 93(12), 1388-1394 (2005). (Pubitemid 41752866)
27. Stam RW, Den Boer Ml, Meijerink JP et al.: Differential mRNA expression of ara-C-metabolizing enzymes explains ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 101(4), 1270-1276 (2003). (Pubitemid 36182495)
28. Galmarini CM, Thomas X, Calvo F et al.: In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br. J. Haematol. 117(4), 860-868 (2002). (Pubitemid 34639247)
29. Jordheim LP, Nguyen-Dumont T, Thomas X, Dumontet C, Tavtigian SV: Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53. Drug Metab. Dispos. 36(12), 2419-2423 (2008).
30. Lamba JK: Genetic factors influencing cytarabine therapy. Pharmacogenomics 10(10), 1657-1674 (2009).
31. Hartford CM, Duan S, Delaney SM et al.: Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113(10), 2145-2153 (2009).
32. Li L, Fridley Bl, Kalari K et al.: Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res. 68(17), 7050-7058 (2009).
33. Claes B, Buysschaert I, Lambrechts D: Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy. Heredity 105(1), 152-160 (2010).
34. Turan N, Katari S, Coutifaris C, Sapienza C: Explaining inter-individual variability in phenotype: is epigenetics up to the challenge? Epigenetics 5(1), 16-19 (2010).
35. Bryant PA, Smyth GK, Robins-Browne R, Curtis N: Detection of gene expression in an individual cell type within a cell mixture using microarray analysis. PLoS ONE 4(2), e4427 (2009).
36. Bryant PA, Smyth GK, Robins-Browne R, Curtis N: Detection of gene expression in an individual cell type within a cell mixture using microarray analysis. PLoS ONE 4(2), e4427 (2009).